|

68Ga-DOTA-NI-FAPI04 PET/CT in Patients With Various Types of Cancer

RECRUITINGEarly 1Sponsored by First Affiliated Hospital of Fujian Medical University
Actively Recruiting
PhaseEarly 1
SponsorFirst Affiliated Hospital of Fujian Medical University
Started2024-04-01
Est. completion2025-04-01
Eligibility
Age18 Years – 80 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06455761

Summary

As a novel radiotracer targeting fibroblast activation protein (FAP), 68Ga-DOTA-NI-FAPI04 is a novel agent incorporating a hypoxia sensitive nitroimidazole(NI)-moiety and a FAP-targeting. In this study, we observed the diagnostic performance of 68Ga-DOTA-NI-FAPI04 PET/CT in patients with different types of cancer, and compared its imaging results with those of 68Ga-FAPI or 18F-FDG PET/CT.

Eligibility

Age: 18 Years – 80 YearsHealthy volunteers accepted
Inclusion Criteria:

Various solid tumors with available histopathological findings; Signed informed consent.

Exclusion Criteria:

pregnant or lactational women; who suffered from severe hepatic and renal insufficiency.

Conditions2

CancerTumor

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.